Glasdegib – Uses, Dosage, Side Effects, Interaction

Glasdegib Maleate is the maleate salt form of glasdegib, an orally bioavailable small-molecule, smoothened (SMO) receptor inhibitor, with potential antineoplastic activity. Upon oral administration, glasdegib targets bind to and inhibit the activity of SMO. This inhibits the activity of the Hedgehog (Hh) signaling pathway and inhibits the growth of tumor cells in which this pathway is aberrantly activated. SMO, a transmembrane protein, is involved in Hh signal transduction. The Hh signaling pathway plays an important role in cellular growth, differentiation, repair, and cancer stem cell (CSC) survival. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies and is associated with uncontrolled cellular proliferation in a variety of cancers.

Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed.^[rx]Glasdegib was developed by Pfizer Inc and approved on November 21, 2018, by the FDA for the treatment of Acute Myeloid Leukemia.^[rx]

In preclinical studies, glasdegib achieved a significant reduction in leukemic stem cell burden in xenograft models and a reduction in the cell population expressing leukemic stem cell markers. In clinical trials, glasdegib demonstrated a marked downregulation of more than 80% of the expression of glioma-associated transcriptional regulator GL11 in the skin. In this same study, 8% of the studied individuals with acute myeloid leukemia achieved morphological complete remission while 31% achieved a stable disease state. The latest clinical trial proved glasdegib to generate an overall survival of 8.3 months which was almost double what has been observed in patients under low-dose cytarabine treatment. As well, there have been reports of dose-dependent QTc prolongation in patients administered with glasdegib.

Indications

• Glasdegib, in combination with cytarabine, is indicated for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are over 75 years old or that have co-morbidities that preclude intensive induction chemotherapy. Acute myeloid leukemia is characterized by abnormal production of myeloblasts, red cells, or platelets. It is considered a cancer of the blood and bone marrow and it is the most common type of acute leukemia in adults.
• Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
• Glasdegib is an orally available small molecule inhibitor of the signaling molecule hedgehog which is used as an antineoplastic agent in the treatment of acute myeloid leukemia.
• Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
• Glasdegib is a sonic hedgehog receptor inhibitor used to treat newly diagnosed acute myeloid leukemia in patients over 75 years who cannot receive intense chemotherapy.
• This drug, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years old or older or who have comorbidities that preclude use of intensive induction chemotherapy.

Acute myeloid leukemia is characterized by abnormal production of myeloblasts, red cells, or platelets. It is considered a cancer of blood and bone marrow and it is the most common type of acute leukemia in adults.

Use in Cancer

Glasdegib maleate is approved to treat:

• Acute myeloid leukemia that is newly diagnosed. It is used with low-dose cytarabine in patients aged 75 years and older or adults who cannot be treated with intensive induction chemotherapy.

Glasdegib maleate is also being studied in the treatment of other types of cancer.

Contraindications

• are allergic to glasdegib or any ingredients of the medication
• are male and are unwilling or unable to use effective birth control
• are female, may become pregnant, and are unwilling or unable to use effective birth control
• are pregnant
• are breast-feeding
• low amount of magnesium in the blood
• low amount of potassium in the blood
• prolonged QT interval on EKG
• chronic heart failure
• abnormal EKG with QT changes from birth
• pregnancy
• a patient who is producing milk and breastfeeding

Dosage

Strengths: 25 mg; 100 mg

Acute Myeloid Leukemia

• 100 mg orally once a day on days 1 to 28 in combination with cytarabine 20 mg subcutaneously 2 times a day on days 1 to 10 of each 28-day cycle in the absence of unacceptable toxicity or loss of disease control; for patients without unacceptable toxicity, treat for a minimum of 6 cycles to allow time for clinical response=

Acute Myeloid Leukemia

75 years or older:

• 100 mg orally once a day on days 1 to 28 in combination with cytarabine 20 mg subcutaneously 2 times a day on days 1 to 10 of each 28-day cycle in the absence of unacceptable toxicity or loss of disease control; for patients without unacceptable toxicity, treat for a minimum of 6 cycles to allow time for clinical response

Dose Adjustments

Dose Modifications for Adverse Reactions:
QTC INTERVAL PROLONGATION ON AT LEAST 2 SEPARATE ELECTROCARDIOGRAMS (ECGS):

• QTc interval greater than 480 ms to 500 ms: Assess electrolyte levels as clinically indicated; review and adjust concomitant medications with known QTc interval-prolonging effects; monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation to less than or equal to 480 ms.
• QTc interval greater than 500 ms: Assess electrolyte levels and supplement as clinically indicated; review and adjust concomitant medications with known QTc interval-prolonging effects; interrupt therapy; resume therapy at a reduced dose of 50 mg once daily when QTc interval returns to within 30 ms of baseline or less than or equal to 480 ms; monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation; consider re-escalating the dose to 100 mg daily if an alternative etiology for the QTc prolongation can be identified.
• QTc interval prolongation with life-threatening arrhythmia: Permanently discontinue therapy.

HEMATOLOGIC TOXICITY:

• Platelets less than 10 GI/L for more than 42 days in the absence of disease: Discontinue this drug and low-dose cytarabine permanently.
• Neutrophil count less than 0.5 GI/L for more than 42 days in the absence of disease: Discontinue this drug and low-dose cytarabine permanently.

NONHEMATOLOGIC TOXICITY:

• Grade 3: Interrupt this drug and/or low-dose cytarabine until symptoms reduce to mild or return to baseline; resume this drug at the same dose level, or at a reduced dose of 50 mg; resume low-dose cytarabine at the same dose level, or at a reduced dose of 10 or 15 mg; if toxicity recurs, discontinue this drug and low-dose cytarabine; if toxicity is attributable to this drug only, low-dose cytarabine may be continued.
• Grade 4: Discontinue this drug and low-dose cytarabine permanently.

DOSE MODIFICATION FOR CONCOMITANT USE WITH MODERATE CYP450 3A4 INDUCERS:

• Avoid concomitant use of this drug with moderate CYP450 3A4 inducers.
• If concomitant use cannot be avoided, increase the dose of this drug as tolerated as shown below:
• After the moderate CYP450 3A4 inducer has been discontinued for 7 days, resume this drug at the dose taken prior to initiating the moderate CYP450 3A4 inducer.

DOSE MODIFICATION OF THIS DRUG WHEN TAKEN WITH MODERATE CYP450 INDUCERS:

• If the current dose is 100 mg once a day: Increase it to 200 mg orally once a day.
• If the current dose is 50 mg orally once a day: Increase it to 100 mg orally once a day.

Administration advice:

• This drug may be taken with or without food.
• Do not split, divide, or crush tablets.
• Administer at the same time each day.
• If a dose is vomited, do not administer a replacement dose; wait until the next scheduled dose is due.
• If a dose is missed or not taken at the usual time, administer the dose as soon as possible and at least 12 hours prior to the next scheduled dose. Return to the normal schedule the following day.
• Do not administer 2 doses within 12 hours.

Monitoring:

• Assess complete blood counts, electrolytes, renal, and hepatic function prior to the initiation of therapy and at least once a week for the first month.
• Monitor electrolytes and renal function once monthly for the duration of therapy.
• Obtain serum creatine kinase levels prior to initiating therapy and as indicated clinically thereafter (e.g., if muscle symptoms are reported).
• Monitor electrocardiograms (ECGs) prior to the initiation of therapy, approximately 1 week after initiation, and then once monthly for the next 2 months to assess for QTc prolongation. Repeat ECG if abnormal. Some patients may require more frequent and ongoing ECG monitoring.

Side Effects

The Most Common

• muscle spasms
• muscle, bone or joint pain
• extreme tiredness
• nausea
• vomiting
• abdominal pain
• constipation
• pain or sores in your mouth or throat
• decreased appetite
• change in the way things taste
• weight loss
• headache
• rash
• swelling of hands or legs
• hair loss
• toothache
• feeling faint, lightheaded, or dizzy; fast or irregular heartbeat
• unusual bruising or bleeding
• fever alone or along with chills, and weakness. or other signs of infection
• decreased urination
• chest pain

More common

• Black, tarry stools
• bleeding gums
• blood in the urine or stools
• chest pain
• chills
• confusion
• cough
• coughing up blood
• decreased frequency or amount of urine
• difficult or labored breathing
• difficulty in swallowing
• dizziness or fainting
• drowsiness
• dry mouth
• fainting
• fast, slow, or irregular heartbeat
• fever
• headache
• increased blood pressure
• increased menstrual flow or vaginal bleeding
• increased thirst
• lightheadedness
• loss of appetite
• loss of consciousness
• lower back or side pain
• mood or mental changes
• muscle pain or cramps
• muscle spasms (tetany) or twitching seizures
• nausea
• nervousness
• nosebleeds
• numbness or tingling in the hands, feet, or lips
• painful or difficult urination
• pale skin
• paralysis
• pinpoint red spots on the skin
• pounding heartbeat
• prolonged bleeding from cuts
• rapid, shallow breathing
• red or black, tarry stools
• red or dark brown urine
• seizures
• sneezing
• sore throat
• stomach pain
• swelling of the face, hands, ankles, or lower legs
• tightness in the chest
• trembling
• troubled breathing with exertion
• ulcers, sores, or white spots in the mouth
• unusual bleeding or bruising
• unusual tiredness or weakness
• vomiting
• weakness or heaviness of the legs
• weight gain
• Bone or muscle pain
• change in taste
• constipation
• cracked lips
• decreased appetite
• diarrhea
• loose tooth
• loss of taste
• skin rash
• thinning or loss of hair
• toothache

Rare

• changes in sense of taste
• decreased appetite
• fatigue
• hair loss
• headache
• muscle, joint, or bone pain
• muscle spasms or tightness
• nausea
• rash
• sores or pain in the mouth or throat
• stomach pain
• toothache or lose tooth
• weakness
• weight loss
• irregular heartbeat (e.g., fast, slow, or pounding heartbeat; shortness of breath; dizziness)
• signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath)
• signs of clotting problems (e.g., unusual nosebleeds, bruising, blood in urine, coughing blood, bleeding gums, cuts that don’t stop bleeding)
• signs of infection (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness)
• signs of kidney failure (e.g., decreased urine production, swelling, fatigue, abdominal pain)
• swelling arms, legs, face
• symptoms of low sodium levels in the blood (e.g., achy, stiff, or uncoordinated muscles; confusion; tiredness; weakness)
• symptoms of pneumonia (e.g., fever or chills, shortness of breath, fatigue, chest pain, cough)
• eye bleeding (e.g., blurred vision, pain when exposed to light, eye bruising)
• severe breathing problems (respiratory failure: blue color to skin, lips, or fingernails; sleepiness; irregular heartbeat; shortness of breath; loss of consciousness)
• signs of bleeding in the stomach (e.g., bloody, black, or tarry stools; spitting up blood; vomiting blood or material that looks like coffee grounds)
• signs of bleeding in the brain (e.g., sudden or severe headache; sudden loss of coordination; vision changes; sudden slurring of speech; or unexplained weakness, numbness, or pain in arm or leg)
• signs of a heart attack (e.g., sudden chest pain or pain radiating to back, down arm, jaw; sensation of fullness of the chest; nausea; vomiting; sweating; anxiety)

Drug Interactions

DRUG	INTERACTION
Abametapir	The serum concentration of Glasdegib can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Glasdegib can be increased when combined with Abatacept.
Abemaciclib	The serum concentration of Abemaciclib can be increased when it is combined with Glasdegib.
Abiraterone	The metabolism of Glasdegib can be decreased when combined with Abiraterone.
Abrocitinib	The serum concentration of Glasdegib can be increased when it is combined with Abrocitinib.
Acrivastine	The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Glasdegib.
Acyclovir	The excretion of Acyclovir can be decreased when combined with Glasdegib.
Adalimumab	The metabolism of Glasdegib can be increased when combined with Adalimumab.
Adenosine	The risk or severity of QTc prolongation can be increased when Adenosine is combined with Glasdegib.
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Glasdegib.
Ajmaline	The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Glasdegib.
Alectinib	Alectinib may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Alfuzosin	The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Glasdegib.
Alimemazine	The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Glasdegib.
Allopurinol	Glasdegib may decrease the excretion rate of Allopurinol which could result in a higher serum level.
Almotriptan	The metabolism of Glasdegib can be decreased when combined with Almotriptan.
Alpelisib	The serum concentration of Alpelisib can be increased when it is combined with Glasdegib.
Amantadine	The risk or severity of QTc prolongation can be increased when Amantadine is combined with Glasdegib.
Ambrisentan	The serum concentration of Ambrisentan can be increased when it is combined with Glasdegib.
Amifampridine	The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Glasdegib.
Aminophenazone	The metabolism of Glasdegib can be decreased when combined with Aminophenazone.
Amiodarone	The metabolism of Glasdegib can be decreased when combined with Amiodarone.
Amisulpride	The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Glasdegib.
Amitriptyline	The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Glasdegib.
Amodiaquine	The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Glasdegib.
Amoxapine	The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Glasdegib.
Amprenavir	The metabolism of Glasdegib can be decreased when combined with Amprenavir.
Anagrelide	The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Glasdegib.
Anakinra	The metabolism of Glasdegib can be increased when combined with Anakinra.
Anastrozole	The metabolism of Glasdegib can be decreased when combined with Anastrozole.
Antazoline	The risk or severity of QTc prolongation can be increased when Antazoline is combined with Glasdegib.
Antipyrine	The metabolism of Glasdegib can be decreased when combined with Antipyrine.
Apalutamide	The serum concentration of Glasdegib can be decreased when it is combined with Apalutamide.
Apixaban	Glasdegib may decrease the excretion rate of Apixaban which could result in a higher serum level.
Apomorphine	The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Glasdegib.
Apremilast	The metabolism of Glasdegib can be increased when combined with Apremilast.
Aprepitant	The metabolism of Glasdegib can be decreased when combined with Aprepitant.
Arformoterol	The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Glasdegib.
Aripiprazole	The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Glasdegib.
Aripiprazole	The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Glasdegib.
Arsenic trioxide	The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Glasdegib.
Artemether	The risk or severity of QTc prolongation can be increased when Artemether is combined with Glasdegib.
Articaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Articaine.
Asciminib	The serum concentration of Glasdegib can be increased when it is combined with Asciminib.
Asenapine	The risk or severity of QTc prolongation can be increased when Asenapine is combined with Glasdegib.
Astemizole	The risk or severity of QTc prolongation can be increased when Astemizole is combined with Glasdegib.
Asunaprevir	The serum concentration of Glasdegib can be increased when it is combined with Asunaprevir.
Atazanavir	The metabolism of Glasdegib can be decreased when combined with Atazanavir.
Atomoxetine	The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Glasdegib.
Atorvastatin	The metabolism of Glasdegib can be decreased when combined with Atorvastatin.
Atropine	The risk or severity of QTc prolongation can be increased when Atropine is combined with Glasdegib.
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Glasdegib.
Avatrombopag	Avatrombopag may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Glasdegib.
Azatadine	The risk or severity of QTc prolongation can be increased when Azatadine is combined with Glasdegib.
Azelastine	The metabolism of Glasdegib can be decreased when combined with Azelastine.
Azithromycin	The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Glasdegib.
Baricitinib	The excretion of Baricitinib can be decreased when combined with Glasdegib.
Beclomethasone	Beclomethasone dipropionate may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Bedaquiline	The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Glasdegib.
Belantamab	The serum concentration of Belantamab mafodotin can be increased when it is combined with Glasdegib.
Belinostat	The serum concentration of Belinostat can be increased when it is combined with Glasdegib.
Belumosudil	Belumosudil may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Bendamustine	The serum concentration of Bendamustine can be increased when it is combined with Glasdegib.
Benzatropine	The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Glasdegib.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Benzocaine.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Benzyl alcohol.
Bepridil	The risk or severity of QTc prolongation can be increased when Bepridil is combined with Glasdegib.
Berotralstat	The serum concentration of Berotralstat can be increased when it is combined with Glasdegib.
Betamethasone	The metabolism of Glasdegib can be increased when combined with Betamethasone.
Betrixaban	The serum concentration of Betrixaban can be increased when it is combined with Glasdegib.
Bexarotene	The metabolism of Glasdegib can be decreased when combined with Bexarotene.
Bezafibrate	The metabolism of Glasdegib can be decreased when combined with Bezafibrate.
Bilastine	The risk or severity of QTc prolongation can be increased when Bilastine is combined with Glasdegib.
Bimekizumab	The metabolism of Glasdegib can be increased when combined with Bimekizumab.
Binimetinib	The serum concentration of Binimetinib can be increased when it is combined with Glasdegib.
Bisoprolol	The serum concentration of Bisoprolol can be increased when it is combined with Glasdegib.
Boceprevir	The metabolism of Glasdegib can be decreased when combined with Boceprevir.
Bortezomib	The serum concentration of Bortezomib can be increased when it is combined with Glasdegib.
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Glasdegib.
Brentuximab	The serum concentration of Brentuximab vedotin can be increased when it is combined with Glasdegib.
Bretylium	The risk or severity of QTc prolongation can be increased when Bretylium is combined with Glasdegib.
Brigatinib	The metabolism of Brigatinib can be decreased when combined with Glasdegib.
Brompheniramine	The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Glasdegib.
Buclizine	The risk or severity of QTc prolongation can be increased when Buclizine is combined with Glasdegib.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Bupivacaine.
Buprenorphine	Buprenorphine may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Buserelin	The risk or severity of QTc prolongation can be increased when Buserelin is combined with Glasdegib.
Butacaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Butacaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Butamben.
Butriptyline	The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Glasdegib.
Cabazitaxel	The serum concentration of Cabazitaxel can be increased when it is combined with Glasdegib.
Cabergoline	The serum concentration of Cabergoline can be increased when it is combined with Glasdegib.
Cabozantinib	The metabolism of Glasdegib can be decreased when combined with Cabozantinib.
Caffeine	Caffeine may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Canagliflozin	The serum concentration of Glasdegib can be increased when it is combined with Canagliflozin.
Canakinumab	The metabolism of Glasdegib can be increased when combined with Canakinumab.
Candesartan	The metabolism of Glasdegib can be decreased when combined with Candesartan cilexetil.
Cannabidiol	Cannabidiol may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Capmatinib	The serum concentration of Glasdegib can be increased when it is combined with Capmatinib.

Capsaicin	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Capsaicin.
Carbamazepine	The metabolism of Glasdegib can be increased when combined with Carbamazepine.
Carbinoxamine	The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Glasdegib.
Carfilzomib	The serum concentration of Carfilzomib can be increased when it is combined with Glasdegib.
Carvedilol	The serum concentration of Glasdegib can be increased when it is combined with Carvedilol.
Cefradine	The excretion of Cefradine can be decreased when combined with Glasdegib.
Celecoxib	Glasdegib may decrease the excretion rate of Celecoxib which could result in a higher serum level.
Celiprolol	The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Glasdegib.
Cenobamate	The serum concentration of Glasdegib can be decreased when it is combined with Cenobamate.
Cephalexin	The excretion of Cephalexin can be decreased when combined with Glasdegib.
Ceritinib	The serum concentration of Ceritinib can be increased when it is combined with Glasdegib.
Cerivastatin	Glasdegib may decrease the excretion rate of Cerivastatin which could result in a higher serum level.
Certolizumab	The metabolism of Glasdegib can be increased when combined with Certolizumab pegol.
Cetirizine	The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Glasdegib.
Chlorcyclizine	The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Glasdegib.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Chloroprocaine.
Chloroquine	The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Glasdegib.
Chlorpheniramine	The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Glasdegib.
Chlorpromazine	The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Glasdegib.
Chlorprothixene	The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Glasdegib.
Cholesterol	Cholesterol may increase the excretion rate of Glasdegib which could result in a lower serum level and potentially a reduction in efficacy.
Cilostazol	The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Glasdegib.
Cimetidine	The metabolism of Glasdegib can be decreased when combined with Cimetidine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Cinchocaine.
Cinnarizine	The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Glasdegib.
Cinoxacin	The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Glasdegib.
Ciprofloxacin	The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Glasdegib.
Cisapride	The risk or severity of QTc prolongation can be increased when Cisapride is combined with Glasdegib.
Citalopram	The risk or severity of QTc prolongation can be increased when Citalopram is combined with Glasdegib.
Cladribine	Glasdegib may decrease the excretion rate of Cladribine which could result in a higher serum level.
Clarithromycin	The metabolism of Glasdegib can be decreased when combined with Clarithromycin.
Clemastine	The risk or severity of QTc prolongation can be increased when Clemastine is combined with Glasdegib.
Clobazam	The serum concentration of Clobazam can be increased when it is combined with Glasdegib.
Clofarabine	Glasdegib may decrease the excretion rate of Clofarabine which could result in a higher serum level.
Clofazimine	The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Glasdegib.
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Glasdegib.
Clomipramine	The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Glasdegib.
Clopidogrel	The metabolism of Glasdegib can be decreased when combined with Clopidogrel.
Clozapine	The risk or severity of QTc prolongation can be increased when Clozapine is combined with Glasdegib.
Cobicistat	The metabolism of Glasdegib can be decreased when combined with Cobicistat.
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Glasdegib.
Cocaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Cocaine.
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Glasdegib.
Conivaptan	The metabolism of Glasdegib can be decreased when combined with Conivaptan.
Conjugated	Glasdegib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
Copanlisib	The serum concentration of Copanlisib can be increased when it is combined with Glasdegib.
Crizotinib	The serum concentration of Crizotinib can be increased when it is combined with Glasdegib.
Curcumin	The metabolism of Glasdegib can be decreased when combined with Curcumin.
Cyclizine	The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Glasdegib.
Cyclophosphamide	The metabolism of Glasdegib can be increased when combined with Cyclophosphamide.
Cyclosporine	The serum concentration of Cyclosporine can be increased when it is combined with Glasdegib.
Cyproheptadine	The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Glasdegib.
Dabigatran	The serum concentration of Dabigatran etexilate can be increased when it is combined with Glasdegib.
Dabrafenib	The serum concentration of Glasdegib can be decreased when it is combined with Dabrafenib.
Daclatasvir	Daclatasvir may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Dacomitinib	The serum concentration of Dacomitinib can be increased when it is combined with Glasdegib.
Dactinomycin	The serum concentration of Dactinomycin can be increased when it is combined with Glasdegib.
Danazol	The metabolism of Glasdegib can be decreased when combined with Danazol.
Dapsone	The metabolism of Glasdegib can be decreased when combined with Dapsone.
Daptomycin	The serum concentration of Daptomycin can be increased when it is combined with Glasdegib.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Glasdegib.
Darolutamide	The serum concentration of Glasdegib can be increased when it is combined with Darolutamide.
Darunavir	The metabolism of Glasdegib can be decreased when combined with Darunavir.
Dasabuvir	Dasabuvir may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Dasatinib	The serum concentration of Dasatinib can be increased when it is combined with Glasdegib.
Daunorubicin	Glasdegib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Deferasirox	The metabolism of Glasdegib can be decreased when combined with Deferasirox.
Degarelix	The risk or severity of QTc prolongation can be increased when Degarelix is combined with Glasdegib.
Delafloxacin	The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Glasdegib.
Delamanid	Glasdegib may increase the QTc-prolonging activities of Delamanid.
Delavirdine	The metabolism of Glasdegib can be decreased when combined with Delavirdine.
Desflurane	The risk or severity of QTc prolongation can be increased when Desflurane is combined with Glasdegib.
Desipramine	The risk or severity of QTc prolongation can be increased when Desipramine is combined with Glasdegib.
Desloratadine	The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Glasdegib.
Desvenlafaxine	The metabolism of Glasdegib can be decreased when combined with Desvenlafaxine.
Deutetrabenazine	The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Deutetrabenazine.
Dexamethasone	The metabolism of Glasdegib can be increased when combined with Dexamethasone.
Dexamethasone	Dexamethasone acetate may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Dexbromphenir	The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Glasdegib.
Dexchlorphenir	The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Glasdegib.
Dexibuprofen	The metabolism of Glasdegib can be decreased when combined with Dexibuprofen.
Diclofenac	The metabolism of Glasdegib can be decreased when combined with Diclofenac.
Diethylstilbestrol	Diethylstilbestrol may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Diflunisal	The metabolism of Glasdegib can be decreased when combined with Diflunisal.
Digitoxin	The serum concentration of Digitoxin can be increased when it is combined with Glasdegib.
Digoxin	Glasdegib may decrease the excretion rate of Digoxin which could result in a higher serum level.
Diltiazem	The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Glasdegib.
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Glasdegib.
Diosmin	The serum concentration of Glasdegib can be increased when it is combined with Diosmin.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Diphenhydramine.
Disopyramide	The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Glasdegib.
Disulfiram	The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Glasdegib.
Dofetilide	The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Glasdegib.
Dolasetron	The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Glasdegib.
Dolutegravir	Glasdegib may decrease the excretion rate of Dolutegravir which could result in a higher serum level.
Domperidone	The risk or severity of QTc prolongation can be increased when Domperidone is combined with Glasdegib.
Donepezil	Glasdegib may decrease the excretion rate of Donepezil which could result in a higher serum level.
Dosulepin	The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Glasdegib.
Doxepin	The risk or severity of QTc prolongation can be increased when Doxepin is combined with Glasdegib.
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Glasdegib.

Doxylamine	The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Glasdegib.
Dronedarone	Glasdegib may increase the QTc-prolonging activities of Dronedarone.
Droperidol	The risk or severity of QTc prolongation can be increased when Droperidol is combined with Glasdegib.
Duvelisib	Glasdegib may decrease the excretion rate of Duvelisib which could result in a higher serum level.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Dyclonine.
Ebastine	The risk or severity of QTc prolongation can be increased when Ebastine is combined with Glasdegib.
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Glasdegib.
Efavirenz	The metabolism of Glasdegib can be decreased when combined with Efavirenz.
Elagolix	The serum concentration of Elagolix can be increased when it is combined with Glasdegib.
Elbasvir	Elbasvir may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Eliglustat	The serum concentration of Glasdegib can be increased when it is combined with Eliglustat.
Eltrombopag	The metabolism of Glasdegib can be decreased when combined with Eltrombopag.
Elvitegravir	The metabolism of Glasdegib can be decreased when combined with Elvitegravir.
Emapalumab	The metabolism of Glasdegib can be increased when combined with Emapalumab.
Emedastine	The risk or severity of QTc prolongation can be increased when Emedastine is combined with Glasdegib.
Emtricitabine	The excretion of Emtricitabine can be decreased when combined with Glasdegib.
Enasidenib	The metabolism of Enasidenib can be decreased when combined with Glasdegib.
Encainide	The risk or severity of QTc prolongation can be increased when Encainide is combined with Glasdegib.
Encorafenib	The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Glasdegib.
Enfortumab vedotin	The serum concentration of Enfortumab vedotin can be increased when it is combined with Glasdegib.
Enoxacin	The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Glasdegib.
Entrectinib	The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Entrectinib.
Enzalutamide	The serum concentration of Glasdegib can be decreased when it is combined with Enzalutamide.
Epinastine	The risk or severity of QTc prolongation can be increased when Epinastine is combined with Glasdegib.
Erdafitinib	The serum concentration of Glasdegib can be increased when it is combined with Erdafitinib.
Ergotamine	The metabolism of Glasdegib can be decreased when combined with Ergotamine.
Eribulin	The risk or severity of QTc prolongation can be increased when Eribulin is combined with Glasdegib.
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Glasdegib.
Ertugliflozin	Glasdegib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level.
Erythromycin	The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Glasdegib.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Glasdegib.
Escitalopram	The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Glasdegib.
Esmolol	The risk or severity of QTc prolongation can be increased when Esmolol is combined with Glasdegib.
Estradiol	Estradiol may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Estradiol acetate	Estradiol acetate may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Estradiol benzoate	Estradiol benzoate may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Estradiol cypionate	Estradiol cypionate may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Estradiol dienanthate	Estradiol dienanthate may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Estradiol valerate	Estradiol valerate may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Estrone sulfate	The excretion of Estrone sulfate can be decreased when combined with Glasdegib.
Eszopiclone	The metabolism of Glasdegib can be decreased when combined with Eszopiclone.
Etanercept	The metabolism of Glasdegib can be increased when combined with Etanercept.
Ethinylestradiol	The metabolism of Glasdegib can be decreased when combined with Ethinylestradiol.
Ethosuximide	The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Glasdegib.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Etidocaine.
Etoposide	The serum concentration of Etoposide can be increased when it is combined with Glasdegib.
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Glasdegib.
Ezetimibe	Glasdegib may decrease the excretion rate of Ezetimibe which could result in a higher serum level.
Ezogabine	The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Glasdegib.
Famotidine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Glasdegib.
Favipiravir	The serum concentration of Glasdegib can be increased when it is combined with Favipiravir.
Febuxostat	The excretion of Glasdegib can be decreased when combined with Febuxostat.
Fedratinib	Fedratinib may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Felbamate	The risk or severity of QTc prolongation can be increased when Felbamate is combined with Glasdegib.
Felodipine	The metabolism of Glasdegib can be decreased when combined with Felodipine.
Fenofibrate	The metabolism of Glasdegib can be decreased when combined with Fenofibrate.
Fexinidazole	The risk or severity of adverse effects can be increased when Glasdegib is combined with Fexinidazole.
Fexofenadine	The serum concentration of Fexofenadine can be increased when it is combined with Glasdegib.
Finerenone	The metabolism of Finerenone can be decreased when combined with Glasdegib.
Flecainide	The risk or severity of QTc prolongation can be increased when Flecainide is combined with Glasdegib.
Flibanserin	The serum concentration of Glasdegib can be increased when it is combined with Flibanserin.
Fluconazole	The metabolism of Glasdegib can be decreased when combined with Fluconazole.
Fluorouracil	The metabolism of Fluorouracil can be decreased when combined with Glasdegib.
Fluoxetine	The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Glasdegib.
Flupentixol	The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Flupentixol.
Fluspirilene	The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Glasdegib.
Fluticasone	The metabolism of Glasdegib can be decreased when combined with Fluticasone.
Fluticasone furoate	The metabolism of Glasdegib can be decreased when combined with Fluticasone furoate.
Fluticasone	The metabolism of Glasdegib can be decreased when combined with Fluticasone propionate.
Fluvastatin	The metabolism of Glasdegib can be decreased when combined with Fluvastatin.
Fluvoxamine	The metabolism of Glasdegib can be decreased when combined with Fluvoxamine.
Folic acid	Glasdegib may decrease the excretion rate of Folic acid which could result in a higher serum level.
Formoterol	The risk or severity of QTc prolongation can be increased when Formoterol is combined with Glasdegib.
Foscarnet	The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Glasdegib.
Fosnetupitant	The metabolism of Glasdegib can be decreased when combined with Fosnetupitant.
Fosphenytoin	The metabolism of Fosphenytoin can be decreased when combined with Glasdegib.
Fostamatinib	Fostamatinib may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Fostemsavir	The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Glasdegib.
Fusidic acid	The metabolism of Glasdegib can be decreased when combined with Fusidic acid.
Futibatinib	The serum concentration of Futibatinib can be increased when it is combined with Glasdegib.
Gadobenic acid	The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Glasdegib.
Galantamine	The risk or severity of QTc prolongation can be increased when Galantamine is combined with Glasdegib.
Ganciclovir	The excretion of Ganciclovir can be decreased when combined with Glasdegib.
Gatifloxacin	The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Glasdegib.
Gefitinib	Gefitinib may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Glasdegib.
Gemfibrozil	The metabolism of Glasdegib can be decreased when combined with Gemfibrozil.
Gemifloxacin	The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Glasdegib.
Gilteritinib	The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Glasdegib.
Glecaprevir	Glasdegib may decrease the excretion rate of Glecaprevir which could result in a higher serum level.
Glyburide	Glasdegib may decrease the excretion rate of Glyburide which could result in a higher serum level.
Golimumab	The metabolism of Glasdegib can be increased when combined with Golimumab.
Goserelin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Glasdegib.
Granisetron	The risk or severity of QTc prolongation can be increased when Granisetron is combined with Glasdegib.
Grazoprevir	Grazoprevir may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Grepafloxacin	The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Glasdegib.
Guanidine	The excretion of Guanidine can be decreased when combined with Glasdegib.
Halofantrine	The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Glasdegib.
Haloperidol	The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Haloperidol.

Histrelin	The risk or severity of QTc prolongation can be increased when Histrelin is combined with Glasdegib.
Hydrochlorothiazide	The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Glasdegib.
Hydrocortisone	The metabolism of Glasdegib can be increased when combined with Hydrocortisone.
Hydroxychloroquine	The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Glasdegib.
Hydroxyzine	The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Hydroxyzine.
Hyoscyamine	The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Glasdegib.
Ibandronate	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Glasdegib.
Ibuprofen	The metabolism of Glasdegib can be decreased when combined with Ibuprofen.
Ibutilide	The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Glasdegib.
Idelalisib	Glasdegib may decrease the excretion rate of Idelalisib which could result in a higher serum level.
Ifosfamide	The metabolism of Glasdegib can be increased when combined with Ifosfamide.
Iloperidone	The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Glasdegib.
Imatinib	The risk or severity of QTc prolongation can be increased when Imatinib is combined with Glasdegib.
Imipramine	The serum concentration of Imipramine can be increased when it is combined with Glasdegib.
Indacaterol	The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Glasdegib.
Indapamide	The risk or severity of QTc prolongation can be increased when Indapamide is combined with Glasdegib.
Indinavir	The metabolism of Glasdegib can be decreased when combined with Indinavir.
Infliximab	The metabolism of Glasdegib can be increased when combined with Infliximab.
Inotersen	The risk or severity of QTc prolongation can be increased when Inotersen is combined with Glasdegib.
Inotuzumab	The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Glasdegib.
Irbesartan	The metabolism of Glasdegib can be decreased when combined with Irbesartan.
Irinotecan	Glasdegib may decrease the excretion rate of Irinotecan which could result in a higher serum level.
Isavuconazole	The serum concentration of Glasdegib can be increased when it is combined with Isavuconazole.
Isavuconazonium	The serum concentration of Glasdegib can be increased when it is combined with Isavuconazonium.
Isoflurane	The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Glasdegib.
Isoniazid	The metabolism of Glasdegib can be decreased when combined with Isoniazid.
Isradipine	The metabolism of Glasdegib can be decreased when combined with Isradipine.
Istradefylline	Istradefylline may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Itraconazole	The metabolism of Glasdegib can be decreased when combined with Itraconazole.
Ivabradine	The risk or severity of QTc prolongation can be increased when Ivabradine is combined with Glasdegib.
Ivacaftor	The serum concentration of Glasdegib can be increased when it is combined with Ivacaftor.
Ivermectin	Glasdegib may decrease the excretion rate of Ivermectin which could result in a higher serum level.
Ivosidenib	The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Ivosidenib.
Ixabepilone	The serum concentration of Glasdegib can be increased when it is combined with Ixabepilone.
Ketamine	The metabolism of Glasdegib can be decreased when combined with Ketamine.
Ketoconazole	The metabolism of Glasdegib can be decreased when combined with Ketoconazole.
Ketoprofen	The metabolism of Glasdegib can be decreased when combined with Ketoprofen.
Ketorolac	The metabolism of Glasdegib can be decreased when combined with Ketorolac.
Lacidipine	The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Glasdegib.
Lamivudine	Glasdegib may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Lamotrigine	The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Glasdegib.
Lansoprazole	Lansoprazole may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Lapatinib	The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Glasdegib.
Larotrectinib	The serum concentration of Larotrectinib can be increased when it is combined with Glasdegib.
Lasmiditan	The serum concentration of Glasdegib can be increased when it is combined with Lasmiditan.
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Glasdegib.
Lefamulin	Lefamulin may increase the QTc-prolonging activities of Glasdegib.
Leflunomide	Glasdegib may decrease the excretion rate of Leflunomide which could result in a higher serum level.
Lemborexant	The serum concentration of Lemborexant can be increased when it is combined with Glasdegib.
Lenvatinib	The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Glasdegib.
Letermovir	Letermovir may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Leuprolide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Glasdegib.
Levacetylmethadol	The risk or severity of QTc prolongation can be increased when Levacetylmethadol is combined with Glasdegib.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Levobupivacaine.
Levocabastine	The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Glasdegib.
Levocetirizine	The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Glasdegib.
Levofloxacin	The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Glasdegib.
Levoketoconazole	The metabolism of Glasdegib can be decreased when combined with Levoketoconazole.
Levomenthol	The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Glasdegib.
Levomilnacipran	The metabolism of Glasdegib can be decreased when combined with Levomilnacipran.
Levosimendan	The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Glasdegib.
Levothyroxine	The metabolism of Glasdegib can be decreased when combined with Levothyroxine.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Lidocaine.
Lidoflazine	The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Glasdegib.
Linagliptin	The metabolism of Glasdegib can be decreased when combined with Linagliptin.
Linzagolix	The serum concentration of Glasdegib can be increased when it is combined with Linzagolix.
Liotrix	The metabolism of Glasdegib can be decreased when combined with Liotrix.
Lofexidine	The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Glasdegib.
Lomefloxacin	The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Glasdegib.
Lomitapide	The serum concentration of Glasdegib can be increased when it is combined with Lomitapide.
Lonafarnib	The metabolism of Glasdegib can be decreased when combined with Lonafarnib.
Loncastuximab	The serum concentration of Loncastuximab tesirine can be increased when it is combined with Glasdegib.
Loperamide	The excretion of Loperamide can be decreased when combined with Glasdegib.
Lopinavir	The metabolism of Glasdegib can be decreased when combined with Lopinavir.
Loratadine	The metabolism of Glasdegib can be decreased when combined with Loratadine.
Losartan	The risk or severity of QTc prolongation can be increased when Losartan is combined with Glasdegib.
Lovastatin	The metabolism of Glasdegib can be decreased when combined with Lovastatin.
Loxapine	The serum concentration of Glasdegib can be increased when it is combined with Loxapine.
Lumacaftor	The serum concentration of Glasdegib can be decreased when it is combined with Lumacaftor.
Lumefantrine	The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Glasdegib.
Lurasidone	The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Glasdegib.
Lusutrombopag	Glasdegib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.
Macimorelin	The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Macimorelin.
Mannitol	The serum concentration of Mannitol can be increased when it is combined with Glasdegib.
Maprotiline	The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Glasdegib.
Maribavir	Maribavir may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Mavacamten	The serum concentration of Glasdegib can be decreased when it is combined with Mavacamten.
Medroxyprogeste	The metabolism of Glasdegib can be decreased when combined with Medroxyprogesterone acetate.
Mefenamic acid	The metabolism of Glasdegib can be decreased when combined with Mefenamic acid.
Mefloquine	The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Glasdegib.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Meloxicam.
Mephenytoin	The metabolism of Glasdegib can be decreased when combined with Mephenytoin.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Mepivacaine.
Mepyramine	The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Glasdegib.
Mesoridazine	The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Glasdegib.
Mestranol	The metabolism of Glasdegib can be decreased when combined with Mestranol.
Metformin	The excretion of Metformin can be decreased when combined with Glasdegib.
Methadone	The risk or severity of QTc prolongation can be increased when Methadone is combined with Glasdegib.
Methimazole	The metabolism of Glasdegib can be decreased when combined with Methimazole.
Methotrexate	Glasdegib may decrease the excretion rate of Methotrexate which could result in a higher serum level.

Methotrimeprazine	The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Glasdegib.
Methoxy	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Glasdegib.
Methsuximide	The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Glasdegib.
Methylene blue	The serum concentration of Glasdegib can be increased when it is combined with Methylene blue.
Metoclopramide	The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Glasdegib.
Metreleptin	The metabolism of Glasdegib can be increased when combined with Metreleptin.
Metronidazole	The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Glasdegib.
Miconazole	The metabolism of Glasdegib can be decreased when combined with Miconazole.
Midostaurin	The metabolism of Glasdegib can be decreased when combined with Midostaurin.
Mifepristone	The serum concentration of Glasdegib can be increased when it is combined with Mifepristone.
Milnacipran	The metabolism of Glasdegib can be decreased when combined with Milnacipran.
Mirabegron	The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Glasdegib.
Mirtazapine	The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Glasdegib.
Mitapivat	The serum concentration of Glasdegib can be increased when it is combined with Mitapivat.
Mitotane	The metabolism of Glasdegib can be increased when combined with Mitotane.
Mitoxantrone	Glasdegib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.
Mizolastine	The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Glasdegib.
Mobocertinib	The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Mobocertinib.
Moexipril	The risk or severity of QTc prolongation can be increased when Moexipril is combined with Glasdegib.
Mometasone	The metabolism of Glasdegib can be decreased when combined with Mometasone furoate.
Montelukast	The metabolism of Glasdegib can be decreased when combined with Montelukast.
Moricizine	The risk or severity of QTc prolongation can be increased when Moricizine is combined with Glasdegib.
Morphine	The serum concentration of Morphine can be increased when it is combined with Glasdegib.
Moxifloxacin	The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Glasdegib.
Mycophenolate	Glasdegib may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.
Nadolol	The excretion of Nadolol can be decreased when combined with Glasdegib.
Nalidixic acid	The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Glasdegib.
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Glasdegib.
Naloxone	The metabolism of Glasdegib can be decreased when combined with Naloxone.
Naproxen	The metabolism of Glasdegib can be decreased when combined with Naproxen.
Nefazodone	The metabolism of Glasdegib can be decreased when combined with Nefazodone.
Nelfinavir	The metabolism of Glasdegib can be decreased when combined with Nelfinavir.
Neratinib	The serum concentration of Glasdegib can be increased when it is combined with Neratinib.
Netupitant	The metabolism of Glasdegib can be decreased when combined with Netupitant.
Nicardipine	The metabolism of Glasdegib can be decreased when combined with Nicardipine.
Nifedipine	The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Glasdegib.
Nilotinib	The metabolism of Glasdegib can be decreased when combined with Nilotinib.
Nilutamide	The metabolism of Glasdegib can be decreased when combined with Nilutamide.
Nilvadipine	The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Glasdegib.
Nimodipine	The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Glasdegib.
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Glasdegib.
Nitrendipine	The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Glasdegib.
Nitrofurantoin	Glasdegib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Norfloxacin	The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Glasdegib.
Norgestimate	The serum concentration of Glasdegib can be increased when it is combined with Norgestimate.
Nortriptyline	The serum concentration of Nortriptyline can be increased when it is combined with Glasdegib.
Novobiocin	Novobiocin may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Octreotide	The risk or severity of QTc prolongation can be increased when Octreotide is combined with Glasdegib.
Ofloxacin	The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Glasdegib.
Olanzapine	The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Glasdegib.
Olodaterol	The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Glasdegib.
Omadacycline	The serum concentration of Omadacycline can be increased when it is combined with Glasdegib.
Ombitasvir	Glasdegib may decrease the excretion rate of Ombitasvir which could result in a higher serum level.
Omeprazole	Omeprazole may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Ondansetron	The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Glasdegib.
Orphenadrine	The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Glasdegib.
Osimertinib	The serum concentration of Osimertinib can be increased when it is combined with Glasdegib.
Oteseconazole	The serum concentration of Glasdegib can be increased when it is combined with Oteseconazole.
Oxaliplatin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Glasdegib.
Oxatomide	The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Glasdegib.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Oxetacaine.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Oxybuprocaine.
Oxybutynin	The metabolism of Glasdegib can be decreased when combined with Oxybutynin.
Oxytocin	The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Glasdegib.
Ozanimod	Glasdegib may decrease the excretion rate of Ozanimod which could result in a higher serum level.
Paclitaxel	The metabolism of Paclitaxel can be decreased when combined with Glasdegib.
Pacritinib	The serum concentration of Glasdegib can be increased when it is combined with Pacritinib.
Palbociclib	Palbociclib may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Paliperidone	The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Glasdegib.
Panobinostat	The serum concentration of Panobinostat can be increased when it is combined with Glasdegib.
Pantoprazole	Pantoprazole may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Papaverine	The risk or severity of QTc prolongation can be increased when Papaverine is combined with Glasdegib.
Paramethadione	The metabolism of Glasdegib can be decreased when combined with Paramethadione.
Paritaprevir	Paritaprevir may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Pasireotide	The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Glasdegib.
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Glasdegib.
Pefloxacin	The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Glasdegib.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Glasdegib.
Pentamidine	The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Glasdegib.
Pentobarbital	The metabolism of Glasdegib can be increased when combined with Pentobarbital.
Perflutren	The risk or severity of QTc prolongation can be increased when Perflutren is combined with Glasdegib.
Perhexiline	The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Glasdegib.
Pheniramine	The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Glasdegib.
Phenobarbital	The metabolism of Glasdegib can be increased when combined with Phenobarbital.
Phenol	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Phenol.
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Glasdegib.
Phenytoin	The metabolism of Phenytoin can be decreased when combined with Glasdegib.
Pibrentasvir	Glasdegib may decrease the excretion rate of Pibrentasvir which could result in a higher serum level.
Pimozide	The risk or severity of QTc prolongation can be increased when Pimozide is combined with Glasdegib.
Pinaverium	The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Glasdegib.
Pioglitazone	The metabolism of Glasdegib can be decreased when combined with Pioglitazone.
Piroxicam	The metabolism of Glasdegib can be decreased when combined with Piroxicam.
Pitavastatin	Glasdegib may decrease the excretion rate of Pitavastatin which could result in a higher serum level.
Pitolisant	The serum concentration of Glasdegib can be decreased when it is combined with Pitolisant.
Pomalidomide	The serum concentration of Pomalidomide can be increased when it is combined with Glasdegib.
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Glasdegib.
Ponesimod	The risk or severity of bradycardia can be increased when Ponesimod is combined with Glasdegib.
Posaconazole	The metabolism of Glasdegib can be decreased when combined with Posaconazole.
Pralatrexate	Glasdegib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pralsetinib	The serum concentration of Pralsetinib can be increased when it is combined with Glasdegib.

Pramocaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Pramocaine.
Pravastatin	Pravastatin may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Prazosin	Glasdegib may decrease the excretion rate of Prazosin which could result in a higher serum level.
Prednisolone	The serum concentration of Prednisolone phosphate can be increased when it is combined with Glasdegib.
Pregabalin	The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Glasdegib.
Prenylamine	The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Glasdegib.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Prilocaine.
Primaquine	The risk or severity of QTc prolongation can be increased when Primaquine is combined with Glasdegib.
Primidone	The metabolism of Glasdegib can be increased when combined with Primidone.
Probenecid	The metabolism of Glasdegib can be increased when combined with Probenecid.
Probucol	The risk or severity of QTc prolongation can be increased when Probucol is combined with Glasdegib.
Procainamide	The risk or severity of QTc prolongation can be increased when Procainamide is combined with Glasdegib.
Procaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Procaine.
Prochlorperazine	The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Glasdegib.
Progesterone	Progesterone may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Promazine	The risk or severity of QTc prolongation can be increased when Promazine is combined with Glasdegib.
Promethazine	The risk or severity of QTc prolongation can be increased when Promethazine is combined with Glasdegib.
Propafenone	The risk or severity of QTc prolongation can be increased when Propafenone is combined with Glasdegib.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Proparacaine.
Propofol	The risk or severity of QTc prolongation can be increased when Propofol is combined with Glasdegib.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Propoxycaine.
Protriptyline	The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Glasdegib.
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Glasdegib.
Pyrimethamine	The metabolism of Glasdegib can be decreased when combined with Pyrimethamine.
Quetiapine	The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Glasdegib.
Quinidine	The serum concentration of Quinidine can be increased when it is combined with Glasdegib.
Quinine	The risk or severity of QTc prolongation can be increased when Quinine is combined with Glasdegib.
Rabeprazole	Rabeprazole may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Raloxifene	Glasdegib may decrease the excretion rate of Raloxifene which could result in a higher serum level.
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Glasdegib.
Regorafenib	The serum concentration of Regorafenib can be increased when it is combined with Glasdegib.
Relebactam	The excretion of Relebactam can be decreased when combined with Glasdegib.
Relugolix	The serum concentration of Relugolix can be increased when it is combined with Glasdegib.
Repaglinide	The metabolism of Glasdegib can be decreased when combined with Repaglinide.
Reserpine	The serum concentration of Glasdegib can be increased when it is combined with Reserpine.
Revefenacin	Glasdegib may decrease the excretion rate of Revefenacin which could result in a higher serum level.
Ribociclib	The metabolism of Glasdegib can be decreased when combined with Ribociclib.
Rifabutin	The metabolism of Glasdegib can be increased when combined with Rifabutin.
Rifampicin	The metabolism of Glasdegib can be increased when combined with Rifampicin.
Rifamycin	The metabolism of Glasdegib can be increased when combined with Rifamycin.
Rifapentine	The metabolism of Glasdegib can be increased when combined with Rifapentine.
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Glasdegib.
Rilonacept	The metabolism of Glasdegib can be increased when combined with Rilonacept.
Rilpivirine	The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Glasdegib.
Riluzole	Glasdegib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Rimegepant	The serum concentration of Rimegepant can be increased when it is combined with Glasdegib.
Riociguat	Glasdegib may decrease the excretion rate of Riociguat which could result in a higher serum level.
Ripretinib	Glasdegib may decrease the excretion rate of Ripretinib which could result in a higher serum level.
Risperidone	The risk or severity of QTc prolongation can be increased when Risperidone is combined with Glasdegib.
Ritonavir	The serum concentration of Glasdegib can be increased when it is combined with Ritonavir.
Rivaroxaban	Glasdegib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Rofecoxib	The metabolism of Glasdegib can be decreased when combined with Rofecoxib.
Rolapitant	Rolapitant may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Glasdegib.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Ropivacaine.
Rosiglitazone	The metabolism of Glasdegib can be decreased when combined with Rosiglitazone.
Rosoxacin	The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Glasdegib.
Rosuvastatin	Glasdegib may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.
Roxadustat	The serum concentration of Glasdegib can be increased when it is combined with Roxadustat.
Roxithromycin	The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Glasdegib.
Rucaparib	Glasdegib may decrease the excretion rate of Rucaparib which could result in a higher serum level.
Rupatadine	The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Glasdegib.
Safinamide	Safinamide may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Salbutamol	The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Glasdegib.
Salmeterol	The metabolism of Glasdegib can be decreased when combined with Salmeterol.
Sapropterin	The serum concentration of Glasdegib can be increased when it is combined with Sapropterin.
Saquinavir	The metabolism of Glasdegib can be decreased when combined with Saquinavir.
Sarecycline	The serum concentration of Glasdegib can be increased when it is combined with Sarecycline.
Satralizumab	The serum concentration of Glasdegib can be decreased when it is combined with Satralizumab.
Secobarbital	The metabolism of Glasdegib can be increased when combined with Secobarbital.
Secukinumab	The metabolism of Glasdegib can be increased when combined with Secukinumab.
Selegiline	The metabolism of Glasdegib can be decreased when combined with Selegiline.
Selexipag	The serum concentration of Selexipag can be increased when it is combined with Glasdegib.
Selpercatinib	The serum concentration of Glasdegib can be increased when it is combined with Selpercatinib.
Selumetinib	Glasdegib may decrease the excretion rate of Selumetinib which could result in a higher serum level.
Sevoflurane	The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Glasdegib.
Sildenafil	The serum concentration of Glasdegib can be increased when it is combined with Sildenafil.
Silodosin	The excretion of Silodosin can be decreased when combined with Glasdegib.
Siltuximab	The metabolism of Glasdegib can be increased when combined with Siltuximab.
Simeprevir	The metabolism of Glasdegib can be decreased when combined with Simeprevir.
Simvastatin	The serum concentration of Glasdegib can be increased when it is combined with Simvastatin.
Sirolimus	The serum concentration of Sirolimus can be increased when it is combined with Glasdegib.
Sitagliptin	The serum concentration of Sitagliptin can be increased when it is combined with Glasdegib.
Sofosbuvir	Glasdegib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Solifenacin	The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Glasdegib.
Solriamfetol	The excretion of Solriamfetol can be decreased when combined with Glasdegib.
Somatrogon	The metabolism of Glasdegib can be increased when combined with Somatrogon.
Sorafenib	The metabolism of Sorafenib can be decreased when combined with Glasdegib.
Sotagliflozin	Sotagliflozin may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Sotalol	The risk or severity of QTc prolongation can be increased when Sotalol is combined with Glasdegib.
Sotorasib	The serum concentration of Glasdegib can be decreased when it is combined with Sotorasib.
Sparfloxacin	The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Glasdegib.
Spironolactone	The metabolism of Glasdegib can be decreased when combined with Spironolactone.
St. John’s Wort	The metabolism of Glasdegib can be increased when combined with St. John’s Wort.
Stiripentol	The metabolism of Glasdegib can be decreased when combined with Stiripentol.
Sulfadiazine	The metabolism of Glasdegib can be decreased when combined with Sulfadiazine.
Sulfamethoxazole	The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Glasdegib.
Sulfaphenazole	The metabolism of Glasdegib can be decreased when combined with Sulfaphenazole.
Sulfasalazine	Sulfasalazine may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Sulfisoxazole	The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Glasdegib.

Sulpiride	The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Glasdegib.
Sultopride	The risk or severity of QTc prolongation can be increased when Sultopride is combined with Glasdegib.
Sumatriptan	Glasdegib may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
Sunitinib	The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Glasdegib.
Suvorexant	The serum concentration of Glasdegib can be increased when it is combined with Suvorexant.
Tacrolimus	The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Glasdegib.
Tafamidis	The serum concentration of Glasdegib can be increased when it is combined with Tafamidis.
Talazoparib	The serum concentration of Talazoparib can be increased when it is combined with Glasdegib.
Tamoxifen	The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Glasdegib.
Taurocholic acid	Taurocholic acid may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Tazarotene	The metabolism of Glasdegib can be decreased when combined with Tazarotene.
Tazemetostat	Glasdegib may decrease the excretion rate of Tazemetostat which could result in a higher serum level.
Technetium	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Glasdegib.
Tecovirimat	The metabolism of Glasdegib can be increased when combined with Tecovirimat.
Tegafur	The metabolism of Tegafur can be decreased when combined with Glasdegib.
Tegaserod	Glasdegib may decrease the excretion rate of Tegaserod which could result in a higher serum level.
Telaprevir	The metabolism of Glasdegib can be decreased when combined with Telaprevir.
Telavancin	The risk or severity of QTc prolongation can be increased when Telavancin is combined with Glasdegib.
Telithromycin	The metabolism of Glasdegib can be decreased when combined with Telithromycin.
Telmisartan	Telmisartan may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Telotristat ethyl	The serum concentration of Glasdegib can be decreased when it is combined with Telotristat ethyl.
Temsirolimus	The serum concentration of Temsirolimus can be increased when it is combined with Glasdegib.
Teniposide	Glasdegib may decrease the excretion rate of Teniposide which could result in a higher serum level.
Tenofovir	The serum concentration of Tenofovir alafenamide can be increased when it is combined with Glasdegib.
Tenofovir	The serum concentration of Tenofovir disoproxil can be increased when it is combined with Glasdegib.
Tepotinib	The serum concentration of Tepotinib can be increased when it is combined with Glasdegib.
Terbinafine	The metabolism of Glasdegib can be decreased when combined with Terbinafine.
Terbutaline	The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Glasdegib.
Terfenadine	The metabolism of Glasdegib can be decreased when combined with Terfenadine.
Teriflunomide	The metabolism of Glasdegib can be decreased when combined with Teriflunomide.
Terlipressin	The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Glasdegib.
Testosterone	Glasdegib may decrease the excretion rate of Testosterone which could result in a higher serum level.
Testosterone	Glasdegib may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone	Glasdegib may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Tetrabenazine	The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Glasdegib.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Tetracaine.
Tezacaftor	The serum concentration of Tezacaftor can be increased when it is combined with Glasdegib.
Theophylline	The metabolism of Glasdegib can be decreased when combined with Theophylline.
Thioridazine	The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Glasdegib.
Thiothixene	The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Glasdegib.
Ticagrelor	The serum concentration of Glasdegib can be increased when it is combined with Ticagrelor.
Ticlopidine	The metabolism of Glasdegib can be decreased when combined with Ticlopidine.
Timolol	The risk or severity of QTc prolongation can be increased when Timolol is combined with Glasdegib.
Tipranavir	The metabolism of Glasdegib can be decreased when combined with Tipranavir.
Tivozanib	Tivozanib may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Tizanidine	The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Glasdegib.
Tocilizumab	The metabolism of Glasdegib can be increased when combined with Tocilizumab.
Tolbutamide	The metabolism of Glasdegib can be decreased when combined with Tolbutamide.
Tolterodine	The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Glasdegib.
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Glasdegib.
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Glasdegib.
Torasemide	The metabolism of Glasdegib can be decreased when combined with Torasemide.
Toremifene	The risk or severity of QTc prolongation can be increased when Toremifene is combined with Glasdegib.
Trametinib	The metabolism of Glasdegib can be decreased when combined with Trametinib.
Trastuzumab e	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Glasdegib.
Trazodone	The risk or severity of QTc prolongation can be increased when Trazodone is combined with Glasdegib.
Treprostinil	The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Glasdegib.
Tretinoin	The metabolism of Glasdegib can be decreased when combined with Tretinoin.
Triclabendazole	The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Glasdegib.
Trilaciclib	Glasdegib may decrease the excretion rate of Trilaciclib which could result in a higher serum level.
Trimebutine	The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Glasdegib.
Trimethadione	The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Glasdegib.
Trimethoprim	The metabolism of Glasdegib can be decreased when combined with Trimethoprim.
Trimipramine	The serum concentration of Trimipramine can be increased when it is combined with Glasdegib.
Triprolidine	The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Glasdegib.
Triptorelin	The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Glasdegib.
Troglitazone	The metabolism of Glasdegib can be decreased when combined with Troglitazone.
Troleandomycin	The metabolism of Glasdegib can be decreased when combined with Troleandomycin.
Trovafloxacin	The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Glasdegib.
Tucatinib	Tucatinib may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Ubrogepant	The serum concentration of Ubrogepant can be increased when it is combined with Glasdegib.
Umbralisib	The serum concentration of Glasdegib can be increased when it is combined with Umbralisib.
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Glasdegib.
Valproic acid	The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Glasdegib.
Vandetanib	The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Glasdegib.
Vardenafil	The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Glasdegib.
Velpatasvir	Velpatasvir may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Vemurafenib	The serum concentration of Glasdegib can be increased when it is combined with Vemurafenib.
Venetoclax	The serum concentration of Venetoclax can be increased when it is combined with Glasdegib.
Venlafaxine	Venlafaxine may increase the excretion rate of Glasdegib which could result in a lower serum level and potentially a reduction in efficacy.
Verapamil	The metabolism of Glasdegib can be decreased when combined with Verapamil.
Vernakalant	The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Glasdegib.
Vilanterol	The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Glasdegib.
Viloxazine	The metabolism of Glasdegib can be decreased when combined with Viloxazine.
Vinblastine	The serum concentration of Vinblastine can be increased when it is combined with Glasdegib.
Vincristine	The excretion of Vincristine can be decreased when combined with Glasdegib.
Vinflunine	The serum concentration of Vinflunine can be increased when it is combined with Glasdegib.
Vismodegib	Vismodegib may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Voclosporin	The serum concentration of Glasdegib can be increased when it is combined with Voclosporin.
Vorapaxar	The serum concentration of Glasdegib can be increased when it is combined with Vorapaxar.
Voriconazole	The serum concentration of Glasdegib can be increased when it is combined with Voriconazole.
Vorinostat	The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Glasdegib.
Vortioxetine	The metabolism of Glasdegib can be decreased when combined with Vortioxetine.
Voxilaprevir	Glasdegib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level.
Zidovudine	Glasdegib may decrease the excretion rate of Zidovudine which could result in a higher serum level.
Zimelidine	The metabolism of Glasdegib can be decreased when combined with Zimelidine.
Ziprasidone	The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Ziprasidone.
Zonisamide	The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Glasdegib.
Zopiclone	The metabolism of Glasdegib can be decreased when combined with Zopiclone.
Zuclopenthixol	The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Glasdegib.

Drug-Food Interactions

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

This medication should not be used during pregnancy, as it may cause harm to the developing baby. This drug can harm a developing fetus.
Verify negative pregnancy status in females of reproductive potential within 7 days prior to initiating therapy. Advise females of reproductive potential to use effective contraception during therapy and for at least 30 days after the last dose. Advise males of the potential risk of exposure through semen and to use effective contraception, including a condom, even after a vasectomy, to avoid drug exposure to a pregnant partner or a female partner of reproductive potential during therapy and for at least 30 days after the last dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. It is not known if this drug is present in semen. Advise males to not donate semen during therapy and for at least 30 days after the last dose. This drug may impair fertility in males of reproductive potential. Men should seek advice on effective fertility preservation before beginning therapy.

Lactation

It is not known if glasdegib passes into breast milk. Breastfeeding is not recommended while taking this medication. There are no data on the presence of this drug or its active metabolites in human milk, the effects of the drug on the breastfed child, or its effect on milk production. Because of the potential for serious adverse reactions in a breastfed child, women taking this drug should not breastfeed during therapy and for at least 30 days after the last dose.

How should this medicine be used?

Glasdegib comes as a tablet to take by mouth. It is usually given with or without food once a day for at least 6 months, or as long as your doctor recommends treatment. Take glasdegib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take glasdegib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole; do not split, chew, or crush them. If you vomit after taking glasdegib, do not take another dose. Continue your regular dosing schedule. Your doctor may need to interrupt your treatment, reduce your dose, or stop your treatment depending on your response to the medication and any side effects that you experience. Be sure to tell your doctor how you are feeling during your treatment with glasdegib.

What special precautions should I follow?

Before taking glasdegib,

• tell your doctor and pharmacist if you are allergic to glasdegib, any other medications, or any of the ingredients in glasdegib tablets. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
• tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, and nutritional supplements you are taking or plan to take. Be sure to mention any of the following: amiodarone (Nexterone, Pacerone), carbamazepine (Carbatrol, Equetro, Tegretol, others), chlorpromazine, cilostazol, citalopram (Celexa), clarithromycin, disopyramide (Norpace), dofetilide, donepezil (Aricept), dronedarone (Multaq), efavirenz (Sustiva, in Atripla, Symfi), escitalopram (Lexapro), flecainide (Tambocor), fluconazole (Diflucan), haloperidol (Haldol), ibutilide (Corvert), indinavir (Crixivan), itraconazole (Sporanox, Onmel), ketaconazole, methadone (Dolophine, Methadose), nefazodone, nelfinavir (Viracept), nevirapine (Viramune), ondansetron (Zofran, Zuplenz), phenobarbital, phenytoin (Dilantin, Phenytek), pimozide (Orap), pioglitazone (Actos, in Oseni, Duetact, Actoplus Met), procainamide, quinidine (in Nuedexta), rifabutin (Mycobutin), rifampin (Rifadin, Rimactane, in Rifater, Rifamate), ritonavir (Norvir, in Viekira Pak, Kaletra, Technivie), sotalol (Betapace, Sorine, Sotylize), and thioridazine. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with glasdegib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
• tell your doctor what herbal products you are taking, especially St. John’s wort.
• tell your doctor if you have or have ever had prolonged QT interval (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death), heart failure (condition in which the heart cannot pump enough blood to other parts of the body), or low levels of magnesium or potassium in your blood.
• tell your doctor if you are breast-feeding. You should not breast-feed during your treatment with glasdegib and for at least 30 days after your final dose.
• you should know that this medication may decrease fertility in men. Talk to your doctor about the risks of taking glasdegib.

References

Show More